Trial reportJournal of assisted reproduction and genetics2011
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.
Trial report in Journal of assisted reproduction and genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.Clinical obesity · 2026 · on this mapPooled it
- Pre-conception weight loss interventions in women with polycystic ovary syndrome and the effect on perinatal outcomes: A quantitative synthesis of surrogate outcomes.Diabetes, obesity & metabolism · 2025Pooled it
- Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.BMC women's health · 2025Pooled it
- Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial.Lipids in health and disease · 2024Trial
- Trial
- Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies.Medicina (Kaunas, Lithuania) · 2026Review
- Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Co-morbid Polycystic Ovarian Syndrome with Idiopathic Intracranial Hypertension.Neuro-ophthalmology (Aeolus Press) · 2023Article
- Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials.Journal of obstetrics and gynaecology of India · 2018Review
- Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.JBRA assisted reproduction · 2018Article
- The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study.Archives of medical science : AMS · 2017Article
- Obesity and reproductive function.Obstetrics and gynecology clinics of North America · 2012Review
- Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates.Journal of human reproductive sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeComparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome.
methodsA total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months.
resultsThere was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH.
conclusionsBoth metformin and orlistat showed a similar effect on weight loss and ovulation rates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.